BindingDB logo
myBDB logout

126 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27692854 100 N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.EBI Boehringer Ingelheim Pharmaceuticals
26509831 29 Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.EBI Shandong University
26191361 6 Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.EBI Emory University
26096680 17 Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.EBI Virginia Commonwealth University
25893046 77 Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.EBI Bristol-Myers Squibb Company
25638498 23 Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists.EBI Zhejiang University
24731275 21 Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.EBI Virginia Commonwealth University
24316669 21 Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors.EBI Zhejiang University
24095757 24 Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents.EBI Virginia Commonwealth University
24090135 201 Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.EBI Sanofi
21539377 62 Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.EBI GlaxoSmithKline
20627722 89 Identification of a sulfonamide series of CCR2 antagonists.EBI GlaxoSmithKline Medicines Research Centre
18811134 41 Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1.EBI GlaxoSmithKline
22957890 174 Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.EBI University of Copenhagen
16629828 11 The discovery of tropane-derived CCR5 receptor antagonists.EBI TBA
23075267 85 Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.EBI Bristol-Myers Squibb Company
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
22901310 18 Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.EBI Virginia Commonwealth University
22770928 15 The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.EBI Virginia Commonwealth University
22608963 109 The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.EBI AstraZeneca
22475558 82 Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.EBI Bristol-Myers Squibb Company
21128663 26 An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).EBI Pfizer Global Research and Development
20542438 41 Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.EBI Minase Research Institute
20561788 33 Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents.EBI Chinese Academy of Sciences
20417098 30 Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists.EBI Roche Palo Alto LLC
20137937 13 Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.EBI Roche Palo Alto
19185490 27 1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.EBI Pfizer Global Research and Development
19171484 42 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.EBI Pfizer Global Research and Development
18194864 20 Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.EBI K£mia, Inc.
18267361 56 Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.EBI Novartis Institutes for BioMedical Research
17118654 21 Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.EBI Ono Pharmaceutical Co., Ltd
16821774 86 Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.EBI Ono Pharmaceutical Co., Ltd.
16198561 99 Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.EBI Novartis Institutes for BioMedical Research
14521412 103 Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.EBI Lindsley F. Kimball Research Institute of The New York Blood Center
11931608 17 Inhibition of protein-protein association by small molecules: approaches and progress.EBI Pfizer Global Research and Development
12639564 23 Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides.EBI Schering-Plough Research Institute
11378372 10 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements.EBI Merck Research Laboratories
22266038 55 Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.EBI AstraZeneca
22225639 29 Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).EBI Bristol-Myers Squibb Company
22033460 38 Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.EBI Genzyme Corp.
21940167 12 Design and synthesis of a library of chemokine antagonists.EBI Novartis Institutes of Biomedical Research
21820898 12 The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents.EBI Virginia Commonwealth University
21658961 72 Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.EBI Ono Pharmaceutical Co. Ltd
21398122 38 Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.EBI Genzyme Corp.
21341682 37 Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.EBI Telik, Inc.
21295478 81 Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.EBI Incyte Corporation
21256008 44 Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.EBI Ono Pharmaceutical Co., Ltd
21036044 43 Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.EBI Incyte Corporation
21035337 38 Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion.EBI GlaxoSmithKline
20855212 56 Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series.EBI Roche Palo Alto
20674358 14 Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents.EBI Chinese Academy of Sciences
20347189 7 Efficient synthesis and identification of novel propane-1,3-diamino bridged CCR5 antagonists with variation on the basic center carrier.EBI Institute of Materia Medica
20457517 21 Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists.EBI Roche Palo Alto LLC
20297846 33 Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI Genzyme Corp.
20207141 2 Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing CCR5 antagonists via functionality inversion approach.EBI Institute of Materia Medica
20176481 15 Evaluation of a 4-aminopiperidine replacement in several series of CCR5 antagonists.EBI Roche Palo Alto
19674898 31 Spiropiperidine CCR5 antagonists.EBI Roche Palo Alto LLC
20005712 14 Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.EBI Minase Research Institute
20004099 52 Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles.EBI Roche Palo Alto
19237282 47 Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.EBI Merck Research Laboratories
19233649 30 [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.EBI GlaxoSmithKline
19167884 16 The design and discovery of novel amide CCR5 antagonists.EBI Pfizer Global Research and Development
19014885 32 Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.EBI Roche Palo Alto LLC
18538451 109 Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.EBI Beijing University of Technology
17389363 2 Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia.EBI University of Minnesota
16872138 2 Chemokine receptor CCR-5 inhibitors produced by Chaetomium globosum.EBI Schering-Plough Research Institute
15497939 2 Inhibition of the human chemokine receptor CCR5 by variecolin and variecolol and isolation of four new variecolin analogues, emericolins A-D, from Emericella aurantiobrunnea.EBI MerLion Pharmaceuticals
15217290 4 Isolation and structure of antagonists of chemokine receptor (CCR5).EBI Merck Research Laboratories
12932138 3 10-Methoxydihydrofuscin, fuscinarin, and fuscin, novel antagonists of the human CCR5 receptor from Oidiodendron griseum.EBI MerLion Pharmaceuticals
17587570 34 Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.EBI Johnson & Johnson Pharmaceutical Research and Development
17461566 11 Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.EBI Merck Research Laboratories
17314043 38 CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives.EBI Berlex Biosciences
17311371 13 Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening.EBI CNRS UMR 7175-LC1
17088058 40 Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.EBI Merck Research Laboratories
17081751 47 CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives.EBI Berlex Biosciences
16884289 26 Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.EBI Merck Research Laboratories
16782336 9 Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.EBI Pfizer Global Research and Development
16698264 37 Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.EBI Merck Research Laboratories
16640339 41 Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.EBI Takeda Pharmaceutical Company Limited
16631366 26 Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.EBI AstraZeneca
16539392 29 Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.EBI Takeda Pharmaceutical Company Limited
16154744 32 Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides.EBI AstraZeneca
15808483 30 Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.EBI Merck Research Laboratories
15771462 125 Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.EBI Pharmaceutical Research Institute
15686896 19 Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.EBI Merck Research Laboratories
15582404 68 Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.EBI AstraZeneca
15454223 9 Three new compounds from the plant Lippia alva as inhibitors of chemokine receptor 5 (CCR5).EBI Schering Plough Research Institute
15177481 16 Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.EBI Merck Research Laboratories
15177445 25 Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.EBI Merck Research Laboratories
15115380 24 Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagoniEBI Schering-Plough Research Institute
15055994 99 Orally bioavailable competitive CCR5 antagonists.EBI Novartis Institutes for BioMedical Research
15012999 166 Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.EBI Merck Research Laboratories
15012998 15 Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.EBI Merck Research Laboratories
15012997 43 Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.EBI Merck Research Laboratories
12639563 2 Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.EBI Schering-Plough Research Institute
12565973 33 Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.EBI Schering-Plough Research Institute
12565944 47 1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains.EBI Merck Research Laboratories
12467630 25 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains.EBI Merck Research Laboratories
12372534 2 Two selective novel triterpene glycosides from sea cucumber, Telenata Ananas: inhibitors of chemokine receptor-5.EBI Schering Plough Research Institute
12270193 23 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV.EBI Merck Research Laboratories
12270192 15 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.EBI Merck Research Laboratories
12086500 59 Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.EBI Schering-Plough Research Institute
11844699 16 CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines.EBI Merck Research Laboratories
11720860 12 Combinatorial synthesis of CCR5 antagonists.EBI Merck Research Laboratories
11720852 51 Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11720851 52 Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11591514 61 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.EBI Merck Research Laboratories
11585438 21 Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.EBI Schering-Plough Research Institute
11585437 17 Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.EBI Schering-Plough Research Institute
11549450 55 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.EBI Merck Research Laboratories
11549449 28 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes.EBI Merck Research Laboratories
11514156 28 Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element.EBI Schering-Plough Research Institute
11311066 76 Design, synthesis, and discovery of a novel CCR1 antagonist.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
11212110 1 Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity.EBI Kyoto University
11206474 51 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.EBI Merck Research Laboratories
11206473 36 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.EBI Merck Research Laboratories
10969972 39 CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.EBI SmithKline Beecham Pharmaceuticals
10821717 29 Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.EBI Takeda Chemical Industries, Ltd.